Lexeo Therapeutics Announces Investor Webcast to Report Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy on Monday, July 15, 2024
2024年7月11日 - 9:00PM
Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic
medicine company dedicated to pioneering treatments for genetically
defined cardiovascular diseases and APOE4-associated Alzheimer’s
disease, today announced that the company will conduct an investor
webcast on Monday, July 15, 2024, at 8:00 AM ET to provide an
interim clinical data update on LX2006, an AAVrh10.hFXN gene
therapy for the treatment of Friedreich ataxia (FA) cardiomyopathy.
The presentation will include an overview of the natural history of
FA cardiomyopathy and summary of clinically meaningful endpoints,
interim data from Lexeo’s ongoing SUNRISE-FA Phase 1/2 clinical
trial (NCT05445323) and the ongoing Weill Cornell Medicine
investigator-initiated trial (NCT05302271), as well as an overview
of program next steps.
To register for and access the conference call and webcast
presentation, please visit
https://ir.lexeotx.com/news-events/events or you can register
directly at this link. The on-demand webcast presentation may be
accessed under the News & Events tab in the Investors section
of the Company’s website. A replay of the webcast will be available
on the website following the presentation.
SUNRISE-FA is a multicenter, 52-week, dose-ascending, open-label
trial evaluating the safety and preliminary efficacy of LX2006 in
patients who have FA cardiomyopathy. LX2006 is administered as a
one-time intravenous infusion to patients in at least two
ascending-dose cohorts with the potential to escalate to a third
cohort at a dose of 1.2x1012 vg/kg. Investigators at Weill
Cornell Medicine are conducting a Phase 1A study of AAVrh.10hFXN,
known as LX2006 at Lexeo, in a single-site, 52-week,
dose-ascending, open-label trial evaluating the safety and
preliminary efficacy of AAVrh.10hFXN in patients who have FA
cardiomyopathy. In the Weill Cornell trial, AAVrh.10hFXN is
administered as a one-time intravenous infusion to patients in two
ascending-dose cohorts with five participants per cohort. In April
2024, Lexeo licensed certain intellectual property rights including
rights to current and future data generated from the ongoing Phase
1A trial of AAVrh.10hFXN conducted by Weill Cornell Medicine.
About Lexeo TherapeuticsLexeo Therapeutics is a
New York City-based, clinical stage genetic medicine company
dedicated to transforming healthcare by applying pioneering science
to fundamentally change how genetically defined cardiovascular
diseases and APOE4-associated Alzheimer’s disease are treated.
Using a stepwise development approach, Lexeo is leveraging early
proof-of-concept functional and biomarker data to advance a
pipeline of cardiovascular and APOE4-associated Alzheimer’s disease
programs.
Forward-Looking StatementsCertain statements in
this press release may constitute “forward-looking statements”
within the meaning of the federal securities laws, including, but
not limited to, statements related to the timing and content of the
LX2006 clinical data update press release, investor
webcast and investor presentations. Words such as “may,” “might,”
“will,” “objective,” “intend,” “should,” “could,” “can,” “would,”
“expect,” “believe,” “design,” “estimate,” “predict,” “potential,”
“develop,” “plan” or the negative of these terms, and similar
expressions, or statements regarding intent, belief, or current
expectations, are forward-looking statements. While Lexeo believes
these forward-looking statements are reasonable, undue reliance
should not be placed on any such forward-looking statements. These
forward-looking statements are based upon current information
available to the company as well as certain estimates and
assumptions and are subject to various risks and uncertainties
(including, without limitation, those set forth in Lexeo’s filings
with the U.S. Securities and Exchange Commission (SEC)), many of
which are beyond the company’s control and subject to change.
Actual results could be materially different from those indicated
by such forward looking statements as a result of many factors,
including but not limited to: risks and uncertainties related to
global macroeconomic conditions and related volatility;
expectations regarding the initiation, progress, and expected
results of Lexeo’s preclinical studies, clinical trials and
research and development programs; the unpredictable relationship
between preclinical study results and clinical study results;
delays in submission of regulatory filings or failure to receive
regulatory approval; liquidity and capital resources; and other
risks and uncertainties identified in Lexeo’s Quarterly Report on
Form 10-Q for the quarterly period ended March 31, 2024, filed with
the SEC on May 9, 2024, and subsequent future filings Lexeo may
make with the SEC. New risks and uncertainties may emerge from time
to time, and it is not possible to predict all risks and
uncertainties. Lexeo claims the protection of the Safe Harbor
contained in the Private Securities Litigation Reform Act of 1995
for forward-looking statements. Lexeo expressly disclaims any
obligation to update or alter any statements whether as a result of
new information, future events or otherwise, except as required by
law.
Media Response:Janine Bogris(201)
245-6838janine.bogris@inizioevoke.com
Investor Response:Stephen Jasper(858)
525-2047stephen@gilmartinir.com
Lexeo Therapeutics (NASDAQ:LXEO)
過去 株価チャート
から 6 2024 まで 7 2024
Lexeo Therapeutics (NASDAQ:LXEO)
過去 株価チャート
から 7 2023 まで 7 2024